Brief Title
Acromegaly Treatment Quality of Life Study
Official Title
Effect of Growth Hormone Receptor Antagonism and Somatostatin Analog Administration on Quality of Life
Brief Summary
The investigators hypothesize that treatment of acromegaly will be associated with an improvement in quality of life compared to active acromegaly. At the same time, they will also be studying the effects of different acromegaly treatments on the quality of life.
Study Type
Observational
Primary Outcome
Acromegaly Quality of Life (ACROQoL) Global Score
Secondary Outcome
The Gastrointestinal Quality of Life Index (GIQLI) Total Score
Condition
Acromegaly
Study Arms / Comparison Groups
Acomegaly with Pegvisomant
Description: Patients receiving pegvisomant monotherapy from own doctor to treat acromegaly.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
126
Start Date
January 2013
Completion Date
December 19, 2016
Primary Completion Date
December 19, 2016
Eligibility Criteria
Inclusion Criteria: - Age 18-90 - Active acromegaly or receiving pegvisomant monotherapy or receiving somatostatin analog monotherapy Exclusion Criteria: - Untreated thyroid or adrenal insufficiency. Subjects on replacement therapy must be stable for at least 3 months prior to entry into the study - Initiation or discontinuation of testosterone or estrogen within 3 months of entry - Pregnant and nursing women
Gender
All
Ages
18 Years - 75 Years
Accepts Healthy Volunteers
No
Contacts
Karen Miller, MD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT01732406
Organization ID
2012P001556
Responsible Party
Principal Investigator
Study Sponsor
Massachusetts General Hospital
Collaborators
Pfizer
Study Sponsor
Karen Miller, MD, Principal Investigator, Massachusetts General Hospital
Verification Date
January 2019